

## Ki-67 Immunoexpression in Gestational Trophoblastic Diseases

Nyein Nyein Soe<sup>\*</sup>, Saw Wut Hmone, Myint Myint Nyein & Myat Mon

Department of Pathology  
University of Medicine 1 (Yangon)

Gestational trophoblastic diseases comprise of hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor having different biological behavior. Ki-67 is a proliferative marker used to evaluate the biological behavior of different tumors. The study was aimed to determine the Ki-67 immunoexpression in gestational trophoblastic diseases and its association in different types of gestational trophoblastic diseases. A cross-sectional, descriptive study was done on 50 cases of gestational trophoblastic diseases, histologically identified as 10 cases of partial hydatidiform mole, 23 cases of complete hydatidiform mole, 9 cases of invasive mole and 8 cases of choriocarcinoma. Immunoexpression of Ki-67 was determined by PAP immunohistochemistry. All cases showed Ki-67 immunopositivity. High Ki-67 labeling index ( $\geq 50\%$  of Ki-67 positivity) was found in 10% of partial hydatidiform mole, 73.9% of complete hydatidiform mole, 33.3% of invasive mole and 100% of choriocarcinoma. Low Ki-67 labeling index ( $< 50\%$  of Ki-67 positivity) was found in 90% of partial hydatidiform mole, 26.1% of complete hydatidiform mole, 66.7% of invasive mole ( $p=0.000$ ). These findings indicated that high Ki-67 labeling index was observed in gestational trophoblastic diseases having worse biological behavior such as complete hydatidiform mole and choriocarcinoma. So this study supports that Ki-67 immunoexpression might predict the biological behavior and prognosis of gestational trophoblastic diseases.

*Key words:* Gestational trophoblastic diseases, Histological types, Ki-67 immunoexpression, Ki-67 labeling index

### INTRODUCTION

Gestational trophoblastic diseases consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilization.<sup>1</sup> They include hydatidiform mole (complete and partial), invasive mole, and frankly malignant choriocarcinoma and placental site trophoblastic tumor.<sup>2</sup> The incidence of gestational trophoblastic disease in the Asian population was 1.95 times higher than in the non-Asian population.<sup>3</sup> The incidence of hydatidiform mole in the UK is one in 714 pregnancies.<sup>4</sup> Recent results indicate that the previously documented higher rates in the Far East have fallen towards the stable levels found in Europe and North America, possibly because of dietary changes.<sup>4</sup>

Hydatidiform mole is associated with increased risk of persistent trophoblastic disease or choriocarcinoma.<sup>2</sup> That is rapidly invasive and metastasizes widely, but once identified responds well to chemotherapy.<sup>2</sup>

The risk of choriocarcinoma in complete hydatidiform mole is 10%-30% and in partial hydatidiform mole is 0.5%-5%.<sup>5</sup> Early diagnosis and biological behaviours of gestational trophoblastic diseases are important for follow up and prognosis of the patients. Ki-67 is a proliferative marker and high Ki-67 immunoexpression is also a marker of poor prognosis.<sup>6</sup> Ki-67 has been established as a valuable reflection of the

---

<sup>\*</sup>To whom correspondence should be addressed.  
Tel: +95-95033466  
E-mail: nyeinnyeinsoe81@gmail.com

tissue proliferative compartment and thus could be of value in studying the biologic behavior of the gestational trophoblastic diseases.<sup>7</sup> Ki-67 immunoeexpression shows variable intensities in different subgroups of hydatidiform mole by determining the labeling index (number of positive nuclei/total number of nuclei) in villous, cytotrophoblasts, syncytiotrophoblasts and stroma cells. Ki-67 labeling index of villous cells, especially cytotrophoblasts, is valuable in diagnosis and differentiation between different subgroups of molar pregnancy, being the highest in complete mole (more than 50%) followed by partial mole (more than 20%).<sup>8</sup>

In this study, the immunoreactivity of Ki-67 was assessed in gestational trophoblastic diseases and its association with different types of gestational trophoblastic diseases was studied. By determining the association of the Ki-67 immunoeexpression and the gestational trophoblastic diseases, it was hoped that useful marker will be found for prediction of gestational trophoblastic diseases.

## MATERIALS AND METHODS

A cross-sectional, descriptive study was done on 50 cases of gestational trophoblastic diseases attending Central Women's Hospital (CWH), Yangon. The biopsied samples sent to the histological section of Pathology Department, CWH were fixed with 10% buffered paraformaldehyde. After finishing the adequate fixation, tissue processing and proper paraffin wax embedding, all the tissue sections were stained with haematoxylin and eosin. Histological grading and types of gestational trophoblastic diseases were described by using WHO classification.<sup>9</sup>

### *Immunohistochemical staining method*

The paraffin blocks were further processed for IHC staining with Ki-67 monoclonal antibody (Mouse Anti-human Ki-67 antigen, Clone: Ki88 Code: MU370-UC BioGenex, Emergo Europe) by using the Peroxidase-

antiperoxidase method. Sections 4 µm thickness were placed on silanised slides and then dried at 37°C overnight and incubated at 60°C for half an hour. These slides were deparaffinized through xylene-ethanol series and washed with PBS (phosphate buffered saline) for 5 minutes, 3 times, followed by washing with distilled water for 5 minutes. Antigen retrieval with 10 mM citrate buffer (pH 6.0) was done by using heat method in microwave oven. Slides were immersed with 0.3% hydrogen peroxide in absolute methanol for 15 minutes to block endogenous peroxidase activity. Then, the slides were washed with PBS for 5 minutes, 3 times and incubated in a moist chamber overnight at 4°C with the primary antibodies: Ki-67 (dilution 1:100).

After incubation is completed, these slides were washed individually with PBS (pH 7.6) for 3 times (each time for 5 minutes and incubated with secondary antibody (Horse Radish peroxidase labeled Goat Anti-mouse IgG) for an hour at room temperature. Then these slides were washed with PBS for 5 minutes, three times. The diaminobenzidine substrate solution was freshly prepared and covered on the sections and was left at room temperature for 15-20 minutes. Then, the slides were washed with distilled water for 5 minutes, twice. Slides were counterstained with haematoxylin for 5-10 seconds and rinsed in water and proceeded in ethanol 70%, 80%, 90%, 100%, xylene III, II, I, 5 minutes each for dehydration and mounted with distene plasticizer xylene (DPX). Ki-67 immunopositivity was observed as brown nuclear staining. In this study, Ki-67 immunoeexpression was determined by semi-quantitative scoring method and Ki-67 labeling index.<sup>8</sup>

Semi-quantitative scoring method was determined by the proportion of positive nuclear staining cells over total numbers of cytotrophoblasts and syncytiotrophoblasts. The distribution of Ki-67 immunopositivity in trophoblastic cells were assessed as negative (equal or less than 10% are

positive cells) and positive (more than 10% are positive cells). Positive immunoreactivity was graded as; weakly positive (1+) - (10-20%), moderately positive (2+) - (21-50%) and strongly positive (3+) - (more than 50%).<sup>8</sup> Two senior pathologists performed to count the immunopositivity of trophoblastic cells and immunohistochemical staining reaction of these cells by using specific grading.

Ki-67 labeling index was determined by counting positive brown nuclear staining cells among 1000 cells of cytotrophoblasts and syncytiotrophoblasts. The labeling index was expressed as percent positive.

$$\text{Ki-67 labeling Index} = \frac{\text{Total no. of positive}}{1000 \text{ cells}} = \text{LI\%}$$

Ki-67 labeling index and the immunoreactivity results were recorded and interpreted.

#### *Data analysis*

Statistical analysis of data was done by using the Statistical Package for Social Science Study (SPSS), version 20. The association between Ki-67 immunoreactivity and different types of gestational trophoblastic diseases was tested using Chi-square test.

## **RESULTS**

### *Age distribution of gestational trophoblastic diseases*

Among 50 cases of gestational trophoblastic diseases, the youngest age of patient was 16 years and the oldest age was 52 years. The highest percentage belongs to the age group between 20-29 years, i.e. 19 cases (38%) of study population followed by over 40 years, 16 cases (32%).

Among 10 cases of partial mole, the youngest age of patient was 17 years and the oldest age was 44 years. The mean age of partial mole was 26 years. In complete hydatidiform mole, the youngest age was 16 years and the oldest was 52 years. The mean age was 34.08 years. Among

9 cases of invasive mole, the youngest age was 20 years and the oldest age was 47 years. The mean age was 35 years. In choriocarcinoma, the youngest age was 29 years and the oldest age was 50 years. The mean age was 38.5 years.

### *Distribution of gestational trophoblastic diseases by histological types*

Among 50 cases of gestational trophoblastic diseases, 23 cases (46%) were complete hydatidiform mole, 10 cases (20%) were partial hydatidiform mole, 9 cases (18%) were invasive mole and 8 cases (16%) were choriocarcinoma.

### *Ki-67 immunoreactivity in gestational trophoblastic diseases*

Ki-67 immunoreactivity was found in all 50 cases of gestational trophoblastic samples. The highest Ki-67 immunoreactivity was found in choriocarcinoma cases (77.50%) and the lowest Ki-67 immunoreactivity was seen in partial mole (31.25%) in this study (Table 1).

Table 1. Ki-67 Immunoreactivity in gestational trophoblastic diseases

Histological types	No. of cases	Mean (%)	Standard deviation	Min	Max
Partial mole	10	31.25	10.09	20	50
Complete mole	23	50.78	12.01	25	80
Invasive mole	9	48.33	16.91	30	70
Choriocarcinoma	8	77.50	10.00	55	90
Total	50	50.71	18.44	20	90

Max=Maximum, Min=Minimum

The mean immunoreactivity of 50 cases of gestational trophoblastic diseases was 50.710±18.438 (%). The median value was 50.00. The minimum expression of Ki-67 immunoreactivity was 20 (%). The maximum immunoreactivity was 90 (%) (Table1).

According to the mean and median value of Ki-67 immunoreactivity in gestational trophoblastic diseases in this study, the best cut-off point for gestational trophoblastic diseases in labeling index score was 50 (%). The score less than 50 (%) was considered as low and more than or equal to 50 (%) as high labeling index score.

*Distribution of Ki-67 labeling index in gestational trophoblastic diseases*

Out of 50 cases of gestational trophoblastic diseases, 29 cases (58%) showed presence of high Ki-67 index scores and 21 cases (42%) showed low index scores. Among complete hydatidiform mole, 17 cases (73.9%) showed high Ki-67 index scores and 6 cases (26.1%) showed low index scores. Out of 10 cases of partial hydatidiform mole, only 1 case (10%) showed high Ki-67 index scores and 9 cases (90%) showed low index scores. Among invasive mole, 3 cases (33.3%) showed high Ki-67 index scores and 6 cases (66.7%) showed low index scores. All 8 cases (100%) of choriocarcinoma showed high Ki-67 index scores (Fig. 1).






Fig. 1. Distribution of Ki-67 labeling index in different types of gestational trophoblastic diseases



A=Partial H mole (H&E x 400)  
B=Complete H mole (H&E x 400)  
C=Invasive mole (H&E x 100)  
D=Choriocarcinoma (H&E x 100)

Fig. 2. H and E staining of different types of GTD



A=Partial H mole (Ki-67 LI=37.5%)  
B=Complete H mole (Ki-67 LI=80%)  
C=Invasive mole (Ki-67 LI=70%)  
D=Choriocarcinoma (Ki-67 LI=90%)

Fig. 3. IHC staining of Ki-67 (Ki-67 labeling index) in different histological types of GTD

*Association of Ki-67 immunoexpression with different histological types of gestational trophoblastic diseases*

Among 10 case of partial hydatidiform mole, 2 cases (20%) showed the intensity of Ki-67 immunoexpression 1+ and 8 cases (80%) showed 2+ intensity. Among complete hydatidiform mole, the 2+ intensity of Ki-67 immunoexpression was found to be (52.2%) of cases and the remaining (47.8%) showed 3+ intensity. Among 9 cases of invasive mole, the intensity 2+ was seen in (66.7%) of cases and 3+ in (33.3%). All 8 cases of choriocarcinoma (100%) showed 3+ intensity of Ki-67 immunoexpression (Fig. 2 & 3).

**DISCUSSION**

Maternal age has an influence on the incidence of gestational trophoblastic disease. There was an excess of molar pregnancies in the extremes of reproductive age.<sup>3</sup> In this study, the age distribution of H mole was 16-52 years. Most of the patients were found to be 20-29 years age group (38%) and the second commonest age group was 40 years and above (32%). Lurain found that advanced or very young maternal age had consistently correlation with higher rates of complete hydatidiform mole.<sup>9</sup> There was a small difference of age incidence in this study compared with the previous studies.

In comparison with Ki-67 immun-expression of partial hydatidiform mole, all cases of complete hydatidiform mole showed a higher Ki-67 intensity with mean Ki-67 immunoreactivity  $50.783 \pm 12.014$  (%). The study done by Ali, *et al.*<sup>8</sup> showed Ki-67 immunexpression of all villous components especially of cytotrophoblasts; being the highest in complete hydatidiform mole ( $68.542 \pm 11.275$ ) followed by partial hydatidiform mole ( $22.5 \pm 16.611$ ).

In this study, all 9 cases of invasive mole showed positive Ki-67 immunexpression with the mean immunoreactivity  $48.33 \pm 16.91$  (%). In the study carried out by Makovitzky, *et al.*<sup>10</sup> the invasive mole labeled strongly positive for Ki-67 antigen. All cases of choriocarcinoma showed strongly positive Ki-67 immunexpression with the mean Ki-67 immunoreactivity  $77.5 \pm 10.0$  (%). The study done by Erfanian, *et al.*<sup>7</sup> showed strongly positive Ki-67 immunexpression in cytotrophoblasts  $80.41 \pm 9.40$  (%) and in syncytiotrophoblasts  $58.75 \pm 18.10$  (%).

In the current study, highest proliferative activity of Ki-67 ( $\geq 50\%$  of Ki-67 labeling index) was found in partial mole (10%), complete hydatidiform mole (73.9%), invasive mole (33.3%) and all cases of choriocarcinoma. Therefore, it might be evident that complete hydatidiform mole was more increasing risk of choriocarcinoma than partial hydatidiform mole.

On the other hand, among the histological subtypes of trophoblastic diseases, partial hydatidiform mole showed the lowest Ki-67 labeling index and choriocarcinoma showed the highest. In comparison with choriocarcinoma, invasive mole showed low Ki-67 labeling index score. There was significantly associated between Ki-67 labeling index and histological subtypes of gestational trophoblastic diseases ( $p=0.000$ ). In the present study, Ki-67 immunexpression was detected in all cases of partial hydatidiform mole (10 cases), complete hydatidiform mole (23 cases),

invasive mole (9 cases) and choriocarcinoma (8 cases). According to the findings, it showed that the higher grade of histological subtypes of gestational trophoblastic diseases, the stronger the intensity of Ki-67 immunexpression. In complete hydatidiform mole and invasive mole, there were no cases of weakly positive (1+) Ki-67 immunexpression.

In comparison of partial hydatidiform mole with complete hydatidiform mole, there were no cases of partial hydatidiform mole showing strongly positive (3+) intensity of Ki-67 immunexpression, whereas 47.8% of complete hydatidiform moles showed strongly positive (3+) intensity. All cases of choriocarcinoma showed strongly positive (3+) Ki-67 immunexpression. There was a significantly association between Ki-67 immunexpression and different histological types of gestational trophoblastic diseases ( $p=0.000$ ).

#### Conclusion

This study was determined Ki-67 immun-expression and Ki-67 labeling index in different types of gestational trophoblastic cases from Central Women's Hospital, Yangon. Ki-67 is a proliferative marker and high Ki-67 immunexpression showed a marker of bad biological behavior and poor prognosis. Early diagnosis and accurate biological behavior is important for gestational trophoblastic diseases because early effective treatment can prevent the progression of the diseases. This is the preliminary study done on association of Ki-67 immunexpression in different histological types of gestational trophoblastic diseases in Myanmar.

The findings of this study showed that the higher grade of histological types of the gestational trophoblastic diseases, the stronger the intensity of Ki-67 immun-expression. The findings support that Ki-67 proliferative marker might be useful in determining the prognosis of gestational trophoblastic diseases and early treatment.

## ACKNOWLEDGEMENT

We would like to express our sincere gratitude to Professor Dr. Zaw Wai Soe, Rector, University of Medicine 1(Yangon) for allowing us to perform this research. We want to express our thanks to Professor Dr. San San Myint, Professor and Head, Obstetrics and Gynaecology Department, University of Medicine 1 (Yangon) for allowing us to collect clinical data of the cases in Central Women's Hospital, Yangon. We would like to thank Associate Professor Dr. Khin Shwe Mar, Department of Pathology, Central Women's Hospital, Yangon for kind permission for specimen collection and suggestions. We would also like to thank laboratory staff of Department of Pathology, Central Women's Hospital and Yangon General Hospital and laboratory staff of University of Medicine 1 (Yangon) for their support.

## REFERENCES

1. Altieri A, Franceschi S, Ferlay J, Smith J & Vecchia CL. Epidemiology and aetiology of gestational trophoblastic diseases. *The Lancet Oncology* 2003; 4: 670-678.
2. Ellenson LH & Pirog EC. The Female Genital Tract. In: *Robbin and Cotran Pathologic Basis of Disease*, 8<sup>th</sup> ed. Elsevier Saunders, Philadelphia, 2010; 1057-1061.
3. Tham BWL, Everard JE, Tidy JA, Drew D & Hancock BW. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. *International Journal of Obstetrics and Gynaecology* 2003; 110: 555-559.
4. Newsom-Davis T & Seckl MJ. Gestational trophoblastic tumours. In: *Shaw Gynaecology*, 4<sup>th</sup> ed. Elsevier, Edinburgh, 2016; 650-664.
5. Merchant SH, Amin MB, Viswanatha DS, Malhotra RK, Moehlenkamp C & Joste NE. P57kip2 immunohistochemistry in early molar pregnancies: Emphasis on its complementary role in the differential diagnosis of hydropic abortuses. *Human Pathology* 2005; 36: 180-186.
6. Urruticoechea A, Smith IE & Dowsett M. Proliferation marker Ki-67 in early breast cancer. *Journal of Clinical Oncology* 2005; 23(28): 7212-7220.
7. Erfanian M, Sharifi N & Omid AA. P63 and Ki-67 expression in trophoblastic disease and spontaneous abortion. *Journal of Research in Medical Sciences* 2009; 14(6): 375-384.
8. Ali SM, Ahmed NY, Abdul Al-Hameed TT & Saeed NF. The role of Ki-67 immunexpression in diagnosis of molar pregnancy and differentiating its subtypes. *American Journal of Research Communication* 2014; 2(4): 64-73.
9. Lurain JR. *In vitro* gestational trophoblastic disease 1: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease and management of hydatidiform mole. *American Journal of Obstetric and Gynaecology* 2010; 531-539.
10. Makovitzky J, Radtke A, Shabani N, Friese K, Gerber B & Mylonas L. Invasive hydatidiform mole: Immunohistochemical labeling of inhibin/activin subunits, Ki-67, p53 and glycodeilin A in a rare case. *Acta Histochemica* 2009; 111: 360-365.